By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ketorolac (eent) (monograph)
Drugs

Ketorolac (eent) (monograph)

https://themeditary.com/drug/ketorolac-eent-monograph-6274.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 13, 2023  Additional Content by TheMediTary.Com

Generic name: acular

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Ketorolac ophthalmic, Acular, Acular ls, Acuvail

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Ketorolac (eent) (monograph)?

Introduction

Prototypical NSAIA; a pyrrolizine carboxylic acid derivative.

Uses for Ketorolac (EENT)

Conjunctivitis

Temporary relief of ocular itching due to seasonal allergic (hay fever, pollinosis) conjunctivitis.

Postoperative Ocular Inflammation

Management of postoperative inflammation associated with cataract extraction.

Postoperative Ocular Pain

Reduction of ocular pain and burning/stinging following corneal refractive surgery and photorefractive keratectomy (PRK).

Ketorolac tromethamine 0.5% preservative-free ophthalmic solution is used for the reduction of ocular pain and photophobia following incisional refractive surgery.

Cystoid Macular Edema

Treatment, with or without concomitant topical corticosteroid therapy, to prevent or relieve postoperative cystoid macular edema associated with cataract extraction† [off-label].

Has been used for the active treatment of chronic aphakic or pseudophakic cystoid macular edema† [off-label].

Inhibition of Intraoperative Miosis

Has been used prophylactically before ocular surgery to prevent or reduce intraoperative miosis† [off-label].

Related/similar drugs

diclofenac ophthalmic, dexamethasone ophthalmic, ketorolac ophthalmic, prednisolone ophthalmic, Pataday, olopatadine ophthalmic, Lotemax

Ketorolac (EENT) Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution.

Avoid contamination of the solution container.

Do not administer while wearing contact lenses.

Preservative-free solution is for single use only in one or both eyes; use immediately after opening and discard any unused portion immediately after administration.

Has been safely administered with other ophthalmic medications (e.g., antibiotics, β-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics).

Dosage

Available as ketorolac tromethamine; dosage expressed in terms of the salt.

Pediatric Patients

Conjunctivitis
Ophthalmic

Children ≥3 years of age: 1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.

Postoperative Ocular Inflammation
Ophthalmic

Children ≥3 years of age: 1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.

Postoperative Ocular Pain
Ophthalmic

Children ≥3 years of age undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.

Children ≥3 years of age undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.

Adults

Conjunctivitis
Ophthalmic

1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.

Postoperative Ocular Inflammation
Ophthalmic

1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.

Postoperative Ocular Pain
Ophthalmic

Patients undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.

Patients undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.

Cystoid Macular Edema
Postoperative Cystoid Macular Edema† [off-label]
Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the eye(s) undergoing surgery every 6–8 hours beginning 24 hours prior to surgery and continuing for 3–4 weeks after surgery.

Chronic Aphakic or Pseudophakic Cystoid Macular Edema† [off-label]
Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the affected eye(s) 4 times daily for 2–3 months.

Detailed Ketorolac ophthalmic dosage information

Warnings

Contraindications

Known hypersensitivity to ketorolac tromethamine or any ingredient in the formulation.

Warnings/Precautions

Warnings

Hematologic Effects

May inhibit platelet aggregation and prolong bleeding time.

May increase bleeding (e.g., hyphemas) of ocular tissues in patients undergoing ocular surgery.

Use with caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time.

Sensitivity Reactions

Cross-sensitivity

Possible cross-sensitivity with aspirin, phenylacetic acid derivatives, and other NSAIAs. Use with caution in patients with history of hypersensitivity to these drugs.

General Precautions

Wound Healing Complications

Possible slow or delayed wound healing; may be potentiated with concomitant adminsitration of topical NSAIAs or topical corticosteroids. (See Specific Drugs under Interactions.)

Ocular Effects

Use may result in keratitis. In susceptible patients, continued use may result in epithelial breakdown, corneal thinning, erosion, ulceration, or perforation, which may be sight-threatening.

If manifestations of corneal epithelial breakdown occur, discontinue immediately and closely monitor corneal health.

Increased risk of sight-threatening, adverse corneal effects in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time; use with caution in such patients.

Use >24 hours prior to surgery or >14 days postoperatively may precipitate or exacerbate adverse corneal effects.

Specific Populations

Pregnancy

Category C. Avoid use in the third trimester because of possible premature closure of the ductus arteriosus.

Lactation

Distributed into milk after systemic administration. Caution if used in nursing women.

Pediatric Use

Safety and efficacy not established in children <3 years of age.

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.

Common Adverse Effects

Ocular stinging and burning.

How should I use Ketorolac (eent) (monograph)

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution.

Avoid contamination of the solution container.

Do not administer while wearing contact lenses.

Preservative-free solution is for single use only in one or both eyes; use immediately after opening and discard any unused portion immediately after administration.

Has been safely administered with other ophthalmic medications (e.g., antibiotics, β-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics).

Dosage

Available as ketorolac tromethamine; dosage expressed in terms of the salt.

Pediatric Patients

Conjunctivitis
Ophthalmic

Children ≥3 years of age: 1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.

Postoperative Ocular Inflammation
Ophthalmic

Children ≥3 years of age: 1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.

Postoperative Ocular Pain
Ophthalmic

Children ≥3 years of age undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.

Children ≥3 years of age undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.

Adults

Conjunctivitis
Ophthalmic

1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.

Postoperative Ocular Inflammation
Ophthalmic

1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.

Postoperative Ocular Pain
Ophthalmic

Patients undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.

Patients undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.

Cystoid Macular Edema
Postoperative Cystoid Macular Edema† [off-label]
Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the eye(s) undergoing surgery every 6–8 hours beginning 24 hours prior to surgery and continuing for 3–4 weeks after surgery.

Chronic Aphakic or Pseudophakic Cystoid Macular Edema† [off-label]
Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the affected eye(s) 4 times daily for 2–3 months.

Detailed Ketorolac ophthalmic dosage information
Ketorolac (eent) (monograph) Dosage information (more detail)

What other drugs will affect Ketorolac (eent) (monograph)?

No formal drug interaction studies to date.

Specific Drugs

Drug

Interaction

Comments

Corticosteroids, ophthalmic

Possible additive effects on delaying wound healing

Additive ocular anti-inflammatory activity

Concomitant use may increase the potential for wound healing complications

Potential for additive effects used to therapeutic advantage

More about Ketorolac (eent) (monograph) (Acular)

Dosage information
Ketorolac (eent) (monograph) Side Effects
During pregnancy
Ketorolac Ophthalmic Solution Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Postoperative Ocular Inflammation
Corneal Refractive Surgery
Seasonal Allergic Conjunctivitis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by